Visfatin/PBEF/Nampt and Other Adipocytokines in Inflammatory Bowel Disease

被引:0
|
作者
Neubauer, Katarzyna [1 ]
Krzystek-Korpacka, Malgorzata [2 ]
机构
[1] Wroclaw Med Univ, Dept Gastroenterol & Hepatol, PL-50556 Wroclaw, Poland
[2] Wroclaw Med Univ, Dept Med Biochem, PL-50556 Wroclaw, Poland
来源
关键词
adipocytokines; visfatin/PBEF/Nampt; adiponectine; inflammatory bowel disease; COLONY-ENHANCING FACTOR; MESENTERIC ADIPOSE-TISSUE; CROHNS-DISEASE; VISFATIN EXPRESSION; CIRCULATING LEVELS; DIABETES-MELLITUS; VISCERAL FAT; ADIPONECTIN; RESISTIN; SECRETION;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Etiopathogenesis of inflammatory bowel disease (IBD), chronic devastating conditions of the gastrointestinal tract, remains unclear. As a consequence, the effective and safe treatment strategy and ideal biochemical disease marker are still missing. IBD are associated with many nutritional problems (cachexia, micro- and macroelements deficiencies) and additionally there is an abnormal visceral fat structure in Crohn's disease. Thus, potential involvement of adipocytokines, fat-derivate mediators, in the development of inflammatory bowel disease is extensively studied. List of adipocytokines is growing and currently involves: visfatin/PBEF/Nampt, resistin, adiponectin, apelin, leptin, hepcidin, vaspin, chemerin, omentin, and RBP-4. Adipocytokines possess pleiotropic properties. Visfatin/PBEF/ Nampt acts as a cytokine, growth factor and enzyme. It is suggested that visfatin/PBEF/Nampt participates in the development of inflammation-related bone disease. Elucidation of role of adipocytokines in inflammatory bowel disease requires further studies (Adv Clin Exp Med 2010, 19, 3, 399-404).
引用
收藏
页码:399 / 404
页数:6
相关论文
共 50 条
  • [1] The therapeutic potential of the pharmacological inhibition of PBEF/NAMPT/Visfatin in inflammatory bowel disease
    Gerner, R.
    Wieser, V.
    Bichler, A.
    Moschen, A.
    Tilg, H.
    JOURNAL OF CROHNS & COLITIS, 2014, 8 : S67 - S67
  • [2] Nampt/PBEF/visfatin and cancer
    Bi, Tie-qiang
    Che, Xiang-ming
    CANCER BIOLOGY & THERAPY, 2010, 10 (02) : 119 - 125
  • [3] Nampt/Visfatin/PBEF研究进展
    盛飞凤
    刘昭前
    中国临床药理学与治疗学, 2009, 14 (12) : 1423 - 1427
  • [4] The role of visfatin (PBEF/Nampt) in pregnancy complications
    Pavlova, Tereza
    Novak, Jan
    Bienertova-Vasku, Julie
    JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 2015, 112 : 102 - 110
  • [5] No inflammation without energy: Inhibition of PBEF/NAMPT/Visfatin as a potential new treatment strategy in inflammatory bowel diseases
    Gerner, R. R.
    Macheiner, S.
    Wieser, V.
    Pfister, A.
    Moschen, A. R.
    Tilg, H.
    TOXICOLOGY LETTERS, 2016, 258 : S136 - S136
  • [6] VISFATIN/NAMPT/PBEF: ROLE IN VASCULAR WALL INFLAMMATION
    Romacho, T.
    Azcutia, V
    Vazquez-Bella, M.
    Cercas, E.
    Ruiz, C.
    Villalobos, L.
    Palacios, E.
    Carraro, R.
    Sanchez-Ferrer, C. F.
    Peiro, C.
    HYPERTENSION, 2009, 54 (05) : 1169 - 1169
  • [7] Visfatin/PBEF/Nampt的研究进展
    朱剑
    刘超
    国际病理科学与临床杂志, 2007, (01) : 81 - 84
  • [8] Nampt/PBEF/Visfatin: A regulator of mammalian health and longevity?
    Yang, Hongying
    Lavu, Siva
    Sinclair, David A.
    EXPERIMENTAL GERONTOLOGY, 2006, 41 (08) : 718 - 726
  • [9] Is PBEF/visfatin/Nampt an authentic adipokine relevant to the metabolic syndrome?
    Jaswinder K. Sethi
    Current Hypertension Reports, 2007, 9
  • [10] Is PBEF/visfatin/Nampt an authentic adipokine relevant to the metabolic syndrome?
    Sethi, Jaswinder K.
    CURRENT HYPERTENSION REPORTS, 2007, 9 (01) : 33 - 38